Loading
Alkermes plc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Nov 2022.
Alkermes plc.: what insiders have been doing
Headquartered in Dublin, Ireland, Alkermes plc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, 85 filings were filed, from 20 insiders.
No insider bought on the market over the period, while 6 insiders filed 22 sales totalling €5.4M. No amount is published for 3 filings, which the totals therefore leave out. The largest single trade was a sale of €1.9M by snyderman nancy lynn MD, published on 3 August 2026, equal to 0.032% of the market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 85 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at 4 purchases and 38 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.48 bn USD and net income of 241.7 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
316
Thresholds
n/a
Buy Volume
€1M
4 ops. · all time
Sell Volume
€10M
38 ops. · all time
Who traded when
BuySaleCraig C. Hopkinson13 sales
David Joseph Gaffin7 sales
Nichols Christian Todd6 sales
Parisi Samuel Joseph2 sales
snyderman nancy lynn MD1 sale
Wright Christopher I1 sale
Since the insiders bought
- +8.9%Entry US$24.71 · Close at T+365 US$26.90
- -18.6%Entry US$30.65 · Close at T+365 US$24.94
- -7.9%Entry US$27.98 · Close at T+365 US$25.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alkermes plc. Buy (bullish), based on 18 analysts. Average price target: US$56.28.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,530 of 24,148 companies
63.0
score / 100
Value50
Quality76
FCF yld7.1%
Earn yld3.6%
EV/EBITDA20.5x
ROE3.9%
Gross mgn87%
Net mgn16%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$39.73
Analyst consensus
18 analystsBuy
US$38.00Target US$56.28(+42%)US$83.00
Income statement
RevenueUS$1.5B
Gross profitUS$1.3B87% margin
EBITDAUS$330.9M22% margin
Net incomeUS$241.7M4.0% margin
Valuation
PER (trailing)104.6x
PER (forward)22.0x
P/Book3.7x
Beta0.27
Balance sheet & cash
Market capUS$6.7B
Total debtUS$70M
Free Cash FlowUS$480.3M
Debt / Equity87%
Profitability & ownership
ROE3.9%
ROA4.2%
% insiders1.4%
% institutions107.5%
Last declaration on 9 October 2026
Declarations316 total
9,164 sharesOrdinary SharesSEC:0001520262-26-000131:0
4,069 shares@ US$40.110.0024% mcap100.0% of flowOrdinary SharesSEC:0001520262-26-000131:1
2,034 shares@ US$41.030.0012% mcap6.2% of flowOrdinary SharesSEC:0001520262-26-000127:0
2,034 shares@ US$48.010.0014% mcap7.5% of flowCommon StockSEC144:0001964306-26-000424
5,000 shares@ US$24.590.0018% mcap1.1% of flowOrdinary SharesSEC:0001520262-26-000118:0
9,000 shares@ US$46.9860.0060% mcap3.8% of flowOrdinary SharesSEC:0001520262-26-000118:1
7,576 shares@ US$49.22610.0053% mcap10.8% of flowCommon StockSEC144:0001964306-26-000396
664 shares@ US$49.65260.0005% mcap1.0% of flowOrdinary SharesSEC:0001520262-26-000116:1
6,912 shares@ US$49.18510.0049% mcap9.9% of flowOrdinary SharesSEC:0001520262-26-000116:0
44,472 shares@ US$50.3480.032% mcap33.8% of flowCommon StockSEC144:0001964306-26-000352
2,034 shares@ US$48.580.0014% mcap7.6% of flowOrdinary SharesSEC:0001520262-26-000109:0
104 shares@ US$19.340.0000% mcap0.0% of flowOrdinary SharesSEC:0001520262-26-000110:0
16,524 shares@ US$46.720.011% mcap11.7% of flowOrdinary SharesSEC:0001520262-26-000111:1
44,472 shares@ US$50.3480.032% mcap33.8% of flowOrdinary SharesSEC:0001520262-26-000111:2
4,896 shares@ US$24.590.0017% mcap1.1% of flowOrdinary SharesSEC:0001520262-26-000110:1
9,000 shares@ US$48.580.0063% mcap3.9% of flowOrdinary SharesSEC:0001520262-26-000110:2
27,948 shares@ US$46.720.019% mcap19.7% of flowOrdinary SharesSEC:0001520262-26-000111:0
2,034 shares@ US$54.030.0016% mcap8.6% of flowOrdinary SharesSEC:0001520262-26-000105:0
9,000 shares@ US$51.51340.0068% mcap4.2% of flowOrdinary sharesSEC144:0001964306-26-000304
5,000 sharesOrdinary SharesSEC:0001520262-26-000103:0
8,300 sharesOrdinary SharesSEC:0001520262-26-000103:1
700 sharesOrdinary SharesSEC:0001520262-26-000103:2
2,000 shares@ US$45.100.0010% mcap53.1% of flowCommon StockSEC144:0001964306-26-000282
2,000 sharesOrdinary SharesSEC:0001520262-26-000101:0
2,034 shares@ US$43.050.0010% mcap6.7% of flowCommon StockSEC144:0001964306-26-000268
25 of 316 declarations
About Alkermes plc.
Alkermes plc. (ticker: ALKS) is a biopharmaceutical company listed on the Nasdaq Global Select Market in the United States, with a strategic focus on neuroscience. Its global headquarters is in Dublin, Ireland, while the company maintains a significant operational and commercial footprint in the United States, where most of its marketing and execution capabilities are concentrated. Founded in 1987, Alkermes evolved from a specialty drug-delivery and formulation technology business into an integrated biopharma company combining development, manufacturing, and commercialization. For investors, it is best understood as a mid-cap specialty pharma name with a commercial base and a meaningful pipeline, exposed to psychiatric, addiction, and neurological disorders. ([alkermes.com](https://www.alkermes.com/about-us?utm_source=openai))
The commercial portfolio is centered on VIVITROL, ARISTADA/ARISTADA INITIO, and LYBALVI, which target long-standing unmet needs in alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Alkermes also highlights its manufacturing capabilities and royalty/manufacturing revenues, giving the group a hybrid profile that combines branded pharmaceuticals with product development and platform expertise. In recent company disclosures, Alkermes has emphasized that its portfolio and pipeline are focused on central nervous system disorders, with a strategy built around expanding existing brands and advancing new clinical assets. ([investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-third-quarter-2025-financial-results/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Alkermes is a focused specialist rather than a broadly diversified large-cap pharma company. Its edge comes from a combination of established brands, medication-delivery know-how, and a commercial infrastructure geared toward therapeutic areas where adherence is often a major challenge. In antipsychotics and addiction medicine, the company competes in crowded markets, but its differentiated formulations and established market presence support a distinct positioning. The company also operates internationally, with activities in the United States, Ireland, and other regions, although its revenue base remains heavily tied to the U.S. market. ([stockanalysis.com](https://stockanalysis.com/stocks/alks/company/?utm_source=openai))
Recent developments are noteworthy. In 2026, Alkermes reported first-quarter results and said it expects to initiate a Phase 3 program for alixorexton in narcolepsy. That matters strategically because it shows the company is trying to broaden its pipeline beyond marketed products and pursue a new opportunity in sleep and neurology. The company continues to report quarterly performance updates and market disclosures that point to ongoing activity across its core franchises. In short, ALKS is a neuroscience-focused health care name listed on Nasdaq in the United States, with upside tied to both commercial execution and future clinical readouts. ([investor.alkermes.com](https://investor.alkermes.com/static-files/fff86401-d90f-4ef5-97ff-16775edb0cbe?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
